Creating a Methyltransferase HTS Assay Using an SAH Riboswitch Part I
Friday, 23 September 2016
Riboswitches were discovered in 2002 by Ron Breaker at Yale as RNA-based intracellular sensors of vitamin derivatives. During the last decade, riboswitches have been identified that bind a range of small biomolecules including nucleotides, amino acids, and ions. Riboswitches exert regulatory control of transcription, translation, splicing, and RNA stability. BellBrook scientists used a riboswitch that
- Published in Epigenetics, HTS Assays, Products
No Comments
BellBrook Labs Receives NIH Funding to Commercialize Methyltransferase Assays for Epigenetic Drug Discovery
Tuesday, 30 August 2016
BellBrook Labs has been awarded an $860,000 Phase II SBIR grant from the National Institutes of General Medical Sciences to develop an innovative methyltransferase assay for epigenetic drug discovery. The company’s scientists engineered a fluorescent light switch into a bacterial metabolite sensor to leap-frog the limitations of conventional reagents. Madison, WI – August 31, 2016
- Published in Company, Epigenetics, News
Discovery on Target Conference 2016
Wednesday, 17 August 2016
Discovery on Target 2016 September 19-22 Westin Boston Waterfront Boston, MA Exhibition Visit Booth #24 to: Discuss BellBrook’s current HTS assays. Share your thoughts on the future of drug discovery. Learn about upcoming AptaFluor™ HTS assays! Presentations/Talks AptaFluor™ Methyltransferase Assay: A Homogenous, Universal HMT Assay Based on a Microbial Riboswitch Tuesday, September 20th – 3:15PM Poster
- Published in News
The Advantages Of The Transcreener Phosphodiesterase Assay
Tuesday, 16 August 2016
There are many phosphodiesterase assay kits currently on the market. Comparing the various assays allows pharmaceutical companies to determine for themselves the advantages of using a Transcreener biochemical assay. At BellBrook Labs, located in Madison, WI, we focus on developing HTS assays which can be used to streamline and enhance the drug discovery process. For
- Published in Products
Fighting Infection’s Ghost
Wednesday, 15 June 2016
Aicardi–Goutières syndrome (AGS) is a rare and brutal genetic condition. Most infants born with the syndrome are asymptomatic at birth, but about 1 in 5 have enlarged spleen and liver, elevated liver enzymes in the blood, decreased platelet level, and abnormal neurological responses. Over the first year of life, things get much worse: episodes of
- Published in Emerging Targets
Viruses take the STING out of innate immunity
Thursday, 09 June 2016
Viral trespassers leave traces of themselves as they overtake cells. The presence of hallmark viral molecules—called PAMPs, for pathogen-associated molecular patterns—allows innate immune system sensors to detect the trail of viral substances as effectively as Sherlock Holmes in miniature. Some of these sensors, or pattern recognition receptors (PRRs), nose out viral DNA and RNA. When
- Published in Emerging Targets
New Publication: TR-FRET Assay for UDP-Glycosyltransferases
Thursday, 26 May 2016
See our latest publication, “Development and Validation of a Universal High-Throughput UDP-Glycosyltransferase Assay with a Time-Resolved FRET Signal” in ASSAY and Drug Development Technologies BellBrook Labs scientist Tom Zielinski collaborated with investigators in Mel Reichman and Preston Donover of the Lankenau Institute for Medical Research to develop a robust assay method for screening and profiling
- Published in News
Inhibition of Methyltransferase SMYD3 Targets Ras-driven Cancers
Wednesday, 04 May 2016
The methyltransferase SMYD3 is overexpressed in several tumor types, and its overexpression correlates with aggressiveness in breast carcinoma. Its epigenetic role has been investigated extensively: SMYD3 methylates histone H4 at K5, stimulating expression of critical oncogenic proteins that drive cell proliferation, invasion and metastasis. However, it has recently been discovered that SMYD3 also methylates non-histone
- Published in Emerging Targets
Unraveling RhoGDIα Regulation
Friday, 15 April 2016
Rho proteins are small, monomeric GTPases in the Ras superfamily that control cell shape and motility by regulating cytoskeletal dynamics. They cycle between a GDP-bound inactive state and a GTP-bound active state. When in the active state, Rho proteins bind to effectors at the plasma membrane, which regulate cellular processes such as cell architecture, intracellular
- Published in Emerging Targets
Bound for Life: The First Irreversible Inhibitor of CDK2
Tuesday, 08 March 2016
Drugs targeting cyclin-dependent kinases (CDKs) have been a hot topic in the development of cancer treatments. Kinases in the CDK family play a significant role in the cell cycle and transcription, and thus in tumor development. The first drug targeting a CDK, a CDK4 inhibitor called palbociclib (Pfizer), was approved in February of 2015 for
- Published in Emerging Targets
Recent Posts
-
Researchers Use ATPase Enzyme Assay to Study SMCHD1 Mutations
An ATPase enzyme assay – for more than ju... -
Researchers Employ GTPase Activity Assay to Investigate Rab Proteins
GTPases are in the limelight in biology and dru... -
Using an ATPase Activity Assay for Drug Discovery
What are ATPases? Many people are familiar with... -
BellBrook Labs Recap of SLAS 2019 in Washington DC.
BellBrook Labs will be exhibiting and have post... -
How Does a Biochemical Kinase Assay Work?
A kinase assay works by simply measuring the ac...
